ASH: Pfizer, swimming in crowded waters, eyes wide impact for sickle cell, hemophilia assets. By Annalee Armstrong Dec 9, 2023 7:00pm. Pfizer ASH 2023 sickle cell disease hemophilia ...

The Institute for Clinical and Economic Review (ICER) published a draft evidence report on crizanlizumab (Adakveo), voxelotor (Oxbryta), and L-glutamine (Endari) for sickle cell disease, as well ...

Cobb, a scientist teacher, says that watching his kids deal with the painful effects of sickle cell is hard, ... Dr. Hardesty works at the Indiana Hemophilia & Thrombosis Center in Indianapolis.

Bioverativ, Bicycle in $424.2M deal targeting hemophilia, sickle cell. Sep. 7, 2017. By Nuala Moran. No Comments. LONDON – Bioverativ Inc. is teaming up with Bicycle Therapeutics Ltd. to develop new ...